Home » Marketing » HTML 5 IS BETTER THAN FLASH?
HTML 5 IS BETTER THAN FLASH?
It's obvious that the web development industry is continuously evolving. It seems that the more things change, the more people are shying away from Flash development and moving towards HTML5.
Why HTML5 over Flash? HTML5 is considered to be much more flexible when compared to adobe flash. It supports cross browser compatibility which is important in this day and age. It can be extremely frustrating to build a website that isn't compatible with mobile browsers, or even different desktop browsers. HTML5 makes cross browser compatibility possible.
Improved interactions is another feature that makes HTML5 more superior to flash. HTML5 allows you to build responsive websites that not only connect with the viewer but it allows for better optimization. Unlike static/flash websites, HTML5 websites tend to keep the viewer more engaged, and interested in what you are delivering to them.
We have to also keep in mind that HTML5 is absolutely free, while flash isn't. If a developer wishes to write their code in a word editor, they can do so without any assistance. Flash on the other hand has a dedicated development environment that must be used to create web pages. The environment has to be purchased in order to actually create anything with flash.
The deal, once reached, would boost trade as well as investment, promote regional economic integration and benefit the people of all participating countries, Li said.
Sun Zhaolong, a researcher at the Academy of Contemporary China and World Studies, wrote in an article that Italy's involvement in the BRI will play a exemplary role in attracting more countries to the platform for international cooperation while allaying concerns of some countries over the initiative.
"I expect the same thing to happen now (about the BRI)," he said.
Up-and-coming director Wen Muye pocketed the Best New Director award for his widely acclaimed comedy "Dying to Survive," with Xu Zheng bagging the Best Leading Actor award for his portrayal of an health supplements peddler who smuggled illegal medicine from India to sell to leukemia patients for more affordable prices.
Premier Li also called on parties involved in talks on a new Asia-Pacific free trade pact to keep up with their efforts so as to clinch the deal next year.
Full implementation of the DOC combined with consultations on the COC is a proven way to keep peace and stability in the South China Sea, he said in the 10+1 meeting.
Italian economist as well as China expert Michele Geraci hailed the MOU signed between the two countries as "a win-win-win for Italy, the rest of Europe as well as China", as well as said he believes more European countries will follow his country's lead and sign up to be involved in the initiative.
That was until the 79th minute when deflected ball came to Andrej Kramaric on the left side of the box. Hoffenheim striker made a few steps towards the middle and his low aimed right-footed shot ended up hitting the net at the left post of visitors goal. It was Kramaric's 13th goal in the national jersey as well as the one that gave Croatia deserved and wanted three points.
SINGAPORE, Nov. 15 (mennhua) — Chinese Premier Li Keqiang on Wednesday called for efforts to upgrade the strategic partnership between China as well as the Association of Southeast Asian Nations (ASEAN), as the two sides adopted an key document to chart the course for their ties till 2030.
Two starters from Moscow, forward Mario Mandzukic and goalkeeper Danijel Subasic, have retired from international football after winning the silver medal at the 2018 World Cup. Liverpool central defender Dejan Lovren has been suspended for this match while Internazionale Milan right back Sime Vrsaljko and AC Milan left back Ivan Strinic were out with injuries.
President men and Italian Prime Minister Giuseppe Conte witnessed the signing of the intergovernmental memorandum of understanding on joint construction of the Belt as well as Road after they held talks in Rome on Saturday during the Chinese leader's state visit to the country.
Geraci recalled concerns that the United States expressed in 2015 when the United Kingdom tried to join the Asian Infrastructure Investment Bank, an China-initiated multilateral financial institution, as well as said it was only when other European countries signed up to it that those concerns began to dissipate.


I'm going to sit this one out.
Sutton: Oh no, what's wrong?
Alex: Do you want me to come to the fashion closet too?
Jane: Do you want to? I'm just going to tell her about the appointment I just had with my gyno.
Alex: I'm going to sit this one out.


text:
Q: Get the Future with belonging Callable in ExecutorCompletionService In my application, my tasks implemented Callable are submitted into ExecutorCompletionService and returning Future instance is stored in a List. Then those Future instances are retrieved one by one as following.
        List<Future< Object>> futureList= new ArrayList<Future < Object> >();

        final ExecutorService pool = Executors.newFixedThreadPool( TASK_SIZE );

        final ExecutorCompletionService<Object>  completionService = new ExecutorCompletionService<Object> (pool);
        for ( AbstractTask callable : taskList) {
                futureList.add( completionService.submit(callable) );
        }
        Object rv=null;
        while(futureList.size() > 0) {
            try{
                Future   ft = completionService.take();
                rv = ft.get();
                System.out.println("task returned value : " + rv);
                futureList.remove(ft);
            }catch(Exception e){
                e.printStackTrace();
            }
        }

Here, the output of each AbstractTask is printed which returned from  rv = ft.get(); . But I want a way to get the AbstractTask also with the returned value. Is there a way to get the name of Callable (in my case AbstractTask) which returned the value when Future.get() ?

A: You can just populate a Map<Future<Object>, AbstractTask> that associates each Future with the task that "created" it.
Complete example:
public class Tasks {
    public static void main(String[] args) throws InterruptedException {
        ExecutorCompletionService<String> service = new ExecutorCompletionService<String>(Executors.newSingleThreadExecutor());

        List<Callable<String>> callables = new ArrayList<>();
        Map<Future<String>, Callable<String>> map = new HashMap<>();

        for (int i = 0; i < 10; i++) {
            final String name = Integer.toString(i);
            Callable<String> c = new Callable<String>() {
                @Override
                public String call() throws Exception {
                    return name;
                }

                @Override
                public String toString() {
                    return name;
                }
            };
            callables.add(c);

            Future<String> future = service.submit(c);
            map.put(future, c);
        }

        for (int i = 0; i < callables.size(); i++) {
            Future<String> future = service.take();
            Callable<String> correspondingTask = map.get(future);
            System.out.println("correspondingTask = " + correspondingTask);
        }
    }
}

redpajama_set_name: RedPajamaStackExchange


Meet Li Li Juan, a former millionaire whose benevolent spirit led her to bankruptcy. The 47-year-old, from northern China's Hebei Province, has adopted 72 abandoned children over the course of 19 years. She spent all her money caring for them, and is now facing a huge debt of over two million yuan.
Li became rich during the 1980s, earning huge profits from her garments business and her investments in iron ore mining. It was around this time that she started taking in sick and disabled children who were abandoned by their parents, and orphaned children whose parents had died in coal mine disasters. She used her two sources of income to provide for all her adopted children.
It was all smooth sailing for a few years, but as luck would have it, hard times fell upon Li in 2008. Her mine was shut down due to urban developments, cutting down a major source of her income. But she continued to care for the children by selling off all her properties and valuables, one at a time.
To make matters worse, Li was diagnosed with early stage lymphatic cancer in the winter of 2011. But after only seven days of treatment, she decided that she had had enough. She prioritized the children over her own health, choosing to spend whatever money she had left on them.
But the money soon ran out and the cost of running her 'adoption home' exceeded her income. Despite donations from friends, relatives, and charitable organisations, she still fell short of the money needed to maintain the home. Her debts kept piling up, and now stand at a whopping two million yuan.
A few kind individuals have offered to adopt Li's orphans, but unfortunately, that's not legally possible. Li never registered her adoption home with officially recognised Social Welfare Centers. According to Li Jing Wen, a representative of the Wu'An Civil Affairs Department, Li's initiative is still a citizen-established non-corporal organisation that does not conform to the law. So she cannot legally give them away for adoption, nor does she have the money to care for them herself.
Although Li is a mother to 72 kids, her relationship with her own son, Xiao Wen, is strained. She claims that her son inspired her to adopt orphans and abandoned children, but Xiao wants nothing to do with her anymore. His anger apparently stems from the fact that Li wasn't there to care for him when he suffered a spinal injury in 2004. Li was caring for an adopted child suffering from hydrocepahlus at the time.
After his surgery, Xiao became severely depressed and refused to speak to Li. He later underwent therapy and now lives with his grandmother.
All this would be enough to break anyone's spirit, but not Li Li Juan's. She continues to care for her 72 adopted children, relying on the help of kind-hearted people to make ends meet.
But Li Juan is not the only angel watching over the fates of Chinese abandoned children. A few months back, we wrote about Kong Zhenian, a 65-year-old woman who has adopted 39 physically and mentally-challenged children in the past 40 years.


text:
Yosokwi Productions uses visual media to share the realities of indigenous community in Colombia
byNadya Hernández
Nov 1, 2018 in Diversity
For some, communication is a powerful tool to make themselves — and their community — visible out of their own contexts. Proof of this is Yosokwi Productions, a collective of photographers, producers and documentary filmmakers from the Indigenous community of Arhuaco in the Sierra Nevada de Santa Marta, Colombia — a place that, according to its inhabitants, is the heart of the world.
The project began in 2002 during a conversation between Amado Villafaña and his Mamo, José de Jesús Izquierdo, the spiritual leader of the community, near the basin of the Guatapuri River. At that time, communication seemed to be the best tool to confront worsening violence in the region, caused by both armed militant groups and military forces.
"We need to look outside for allies, we need to broadcast what's happening here," said "Mamo Donki," to Villafaña.
From that point forward, two main ideas have motivated Villafaña's work: self-representation of his people and collective ownership of knowledge and forms of communication — in contrast to the emphasis on individual rights in non-Indigenous communities.
The project began as Zhigoneshi Communications, inside the Organization Gonawindúa Tayrona — the term Zhigoneshi can be translated as "you help me, I help you" — and consisted of three Indigenous communities from the Sierra mountains: the Koguis, Wiwa and Arhuacos. Later each community formed its own collective, and Yosokwi became the Arhuaco voice in the Tayrona Indigenous Confederation, the Arhuaco's community organization.
"The initial goal was to create a film about who we are and how we think about this land," Villafaña explains.
Its initial work was experimental, but Yosokwi later gained support from individuals like Stephen Ferry, a photographer with National Geographic, who helped them acquire equipment and access training workshops. Other opportunities for collaboration later arose, such as with the anthropologist Pablo Mora, the Pontifical Xavierian University and the Avina Foundation.
Today Yosokwi has compiled an archive of more than 600 hours of film and 50,000 photographs. Its documentaries have been shown in film festivals throughout the world and in movie theaters in Colombia. Some of its films have received awards and recognitions, such as the Audience Award from the Panorama Festival for Colombian Film and the Award for Best Documentary Film at the Espiello Festival in Spain. Each work offers an account of the Arhuaco community's understanding of the world, its vision and its theories about the origin of the universe.
For Villafaña, there's a fundamental difference between his organization's work and that of mainstream media: "The mass media has manipulated things over the years. Communication should be real; without staging, without deception." Villafaña also draws a parallel between a camera and a machete: "These tools are useful for whatever purpose you ascribe to them." If used incorrectly, they can cause harm, he says.
One of the main challenges for Yosokwi Productions has been to transition from its tradition of predominantly oral communication to the use of visually focused communication. "Now one hears through his eyes," says Villafaña.
Visual and multimedia communication has been the method through which they have presented their message to the world in an effort to raise consciousness about various issues. The protection of nature, the fight against mining and respect for autonomy are at the heart of the causes they defend.
"With their entry into using this new form of communication, the Arhuacos are leveraging an effective instrument that increases the effectiveness of their struggle to defend the Sierra region," says professor Guillermo Padilla, who holds a doctorate in Latin American Studies with a focus on Legal Anthropology.
Among Yosokwi's main productions are Big Words, Nabusimake, Naboba and Resistance. These documentaries were initially created in the Arhuaco, Wiwa and Kogui languages, and later subtitled in Spanish, English and French.
Villafaña says that a move to new forms of communication was a response to the question, "How do we continue to exist?" He thinks that other Indigenous organizations should use their own voices to tell the world who they are and fight for the causes they care about.
"We are not alone," he says, "but if we remain silent, it will be as if we were."
*Thank you to Ginna Rivera and Guillermo Padilla, who conducted the interview with Amado Villafaña in the heart of the world (Sierra Nevada de Santa Marta, Colombia)
Main image shows Amado Villafaña, courtesy of Yosokwi Productions.

redpajama_set_name: RedPajamaCommonCrawl


text:
Вюргассенська атомна електростанція (, KWW) — закрита атомна електростанція в Німеччині з одним киплячим ядерним реактором (BWR) першого покоління потужністю 670 МВт. АЕС розташована у Вюргассені — частині міста Беверунген в східній Вестфалії в районі Гьокстер, землі Північний Рейн — Вестфалія.

Електростанція експлуатувалася з 1975 року по 26 серпня 1994 року. На початку вересня 1994 року під час планової перевірки були виявлені тріщини довжиною до 60 мм в сталевій оболонці активної зони реактору. АЕС була остаточно закрита 14 квітня 1994 року і знаходиться на стадії демонтажу.

Будувався протягом трьох років і діяв з 1971 року по 26 серпня 1994 року. Під час планового капітального ремонту в сталевій оболонці активної зони реактора були виявлені волосяні тріщини. У 1995 році після ретельного розслідування оператор подав заявку на виведення з експлуатації та знесення з економічних причин. Це було надано ядерним регулюючим органом у 1997 році. Протягом 17 років, до 2014 року, АЕС демонтували, а потім звільняли від радіоактивних речовин, що загалом коштувало понад мільярд євро. З 455 тис. тонн підривної маси було утворено близько 5000 тонн радіоактивних відходів. Будівлі, що залишилися, можуть бути демонтовані лише після повного розчищення тимчасового сховища низько- та середньоактивних радіоактивних відходів на майданчику. Це вимагає прийняття федерального репозиторію. До того часу АЕС залишається в межах Закону про атомну енергетику. У березні 2020 року було оголошено, що центральне сховище вхідних матеріалів для сховища Konrad буде побудовано на місці для подальшого використання.

Демонтаж
Спочатку планувалося, що електростанція буде працювати до 2010 року. У жовтні 1994 року TÜV у співпраці з Інститутом випробувань матеріалів Штутгартського університету виявив волосяні тріщини в сталевому циліндрі (оболочці активної зони) на активній зоні реактора під час планової роботи. огляд, який мав довжину до 60 мм. Не вдалося визначити, чи з'явилися ці тріщини вже під час будівництва чи лише під час експлуатації. Сталева оболонка має завдання проводити тепло і не повинна стримувати тиск. Міжкристалічне корозійне розтріскування під напругою було визначено як механізм утворення тріщин в кожусі сердечника та пластинах решітки сердечника на основі двох досліджених зразків матеріалу. Причину вбачають у складі матеріалу та в обробці відпалу під час виробництва, що викликало сенсибілізацію.

Орган ядерного нагляду подав запит на заміну циліндра, і було оголошено нову процедуру затвердження. Для PreussenElektra це виявилося неекономічним. Вона припускала, що основні установки будуть повністю оновлені, що коштувало б принаймні 200 мільйонів марок і призвело до дворічної зупинки. 2 червня 1995 року PreussenElektra оголосила про свій намір закрити атомну електростанцію у Вюргассені з економічних міркувань Міністерству економіки, малих і середніх підприємств і технологій землі Північний Рейн-Вестфалія, яке займається ядерним ліцензуванням. та наглядовий орган.

Це було значною фінансовою втратою для міста Беверунген, оскільки воно отримало мільйонні надходження від торгових податків, поки електростанція працювала.

Посилання
 Дані про Würgassen KKW

Дані енергоблоку
АЕС має один енергоблок, який протягом експлуатаційного періоду виробив 72 922 ГВт-год електроенергії:

Примітки

Атомні електростанції Німеччини

redpajama_set_name: RedPajamaWikipedia


text:
Repligen (RGEN) Q2 2019 Earnings Call Transcript
RGEN earnings call for the period ending June 30, 2019.
Repligen (NASDAQ:RGEN)
Aug 01, 2019, 8:30 a.m. ET
Good day, ladies and gentlemen, and welcome to Repligen Corporation second-quarter 2019 earnings conference call. My name is Haley, and I will be the operator for your call this morning. [Operator instructions] Please note, this event is being recorded. I would now like to turn the conference over to your host for today's call, Sondra Newman, global head of investor relations.
Please go ahead.
Sondra Newman -- Global Head of Investor Relations
Great. Haley, thank you. Good morning, and thanks to everyone for joining our call. Today, we're covering financial results for Repligen's second fiscal quarter of 2019.
We'll review recent business events and update our financial guidance for the full year. Repligen president and CEO, Tony Hunt, will cover our business highlights; and our CFO, Jon Snodgres will provide a financial report. As a reminder, the forward-looking statements that we make during this call, including those regarding our business goals and expectations for the financial performance of the company, are subject to risks and uncertainties that may cause actual events or results to differ. Additional information concerning risk factors is included in our annual report on Form 10-K, the current report on Form 8-K, which we are filing today, and other filings that we make with the SEC.
Today's comments reflect management's current views, which could change as a result of new information, future events or otherwise. The company does not oblige or commit itself to update forward-looking statements, except as required by law. During this call, we are providing non-GAAP results and guidance. Reconciliations of GAAP to non-GAAP financial measures are included in the press release that we issued this morning, which is posted to Repligen's website and on sec.gov.
Non-GAAP figures in today's report include the following: revenue growth at constant currency; gross profit and gross margin; operating expenses, including R&D and SG&A operating income and operating margin; income tax expense; net income and earnings per share; as well as EBITDA and adjusted EBITDA. These adjusted financial measures should not be viewed as alternative to GAAP measures but are intended to better enable investors to benchmark Repligen's current results against historical performance and the performance of peers when evaluating investment opportunities. Now I'll turn the call over to Tony Hunt.
Tony Hunt -- President and Chief Executive Officer
Thank you, Sondra, and good morning, everyone. Q2 was an excellent and important quarter for the company as our team continues to execute on our financial and strategic goals. Financially, our overall performance was well-ahead of our expectations, delivering 46% organic growth in the second quarter and 42% organic growth in the first half of 2019. Strength in the quarter was across all of our franchises with filtration, chromatography and proteins businesses, each recording organic revenue growth above 40%.
Throughout the first half of this year, order load has remained strong, and we are confident that the momentum in the first half, specifically in filtration and chromatography, will carry over into the second half of this year. We clearly have tougher comps in H2, including a flat proteins business, but we still expect overall organic growth for 2019 to be in the range of 29% to 31%. Strategically, we signed a very important deal in April to acquire C Technologies, which we closed in late May. This adds a fourth franchise for Repligen and moves us into process analytics with a focus on at-line and in-line protein concentration measurement.
C Technologies, innovative protein concentration measurement systems also complement our systems, where we can now look to incorporating this technology into our filtration products. Integration activities are well under way, and we have made good progress on our three target areas. Number one is commercial, where our goal is to build out the sales team, so we have the right coverage in each of our main regions of North America, Europe and Asia-Pac and realize the full potential of this technology. To date, we have hired three of the seven sales specialists with the goal of completing the hiring by the end of the year.
Number two is finance, where our goal will be to align C Technologies to Repligen and public company standards. We are actively building up the finance team in Bridgewater, New Jersey, which we expect to have in place by the end of this quarter. And finally, R&D, where we are increasing our investments in the development of next-gen FlowVPE technology, a disruptive technology in our industry for in-line measurement of protein concentration. Again, there's good alignment here between our teams with the care investment plan in place for the next 18 months.
Turning now to C Technologies business performance. For our one month of ownership in June, sales came in at $2.2 million, and the business is on track to meet our $16 million to $17 million goal for the seven months of ownership in 2019. Finally, during the second quarter and into July, we successfully executed on two follow-on financings, raising approximately $600 million and having approximately $290 million in cash to our balance sheet after paying for C Technologies and exchanging our 2016 notes. This puts us in a very strong financial position from which to execute on internal investments and external opportunities as they arise.
So moving now to our Q2 results. As reported today, we had a record quarter with $70.7 million in sales and adjusted operating margins north of 28%. The story of the quarter was, again, the across-the-board strength in all three franchises and the increased traction for our products at gene therapy accounts. In filtration, our ATF product line had another record quarter.
We continue to see companies scaling up ATF for late-stage and commercial processes. We are very happy with the funnel development with ATF trials up 25% in Q2 versus Q1. Single-use demand continues to be strong, and we have a number of customers moving into commercial manufacturing later this year and into 2020. Our hollow fiber business also had a very strong quarter.
Year over year growth was led by our TFF systems and our single-use flow path assemblies, where 25% of the revenue came from gene therapy accounts. Revenue synergies for Spectrum came in over $3 million for the quarter and over $6 million through the first half of 2019. Overall, revenue synergies are now tracking north of $11 million, which has us well ahead of our three-year goal to deliver between $15 million and $20 million in revenue synergies from this deal. Finally, our SIUS flat sheet TFF cassette business continues to perform well with another strong quarter and first half of this year.
We continue to seek platforming of the technology of key accounts with our next-gen SIUS product line set to launch in late Q4. We are well-positioned with this technology for 2020. Moving to chromatography. Our OPUS prepacked column business delivered another outstanding quarter with revenues well north of 50% year on year.
The story in the quarter was the across-the-board demand for all column sizes and the continued uptick in demand from gene therapy customers. Through the first half of 2019, gene therapy accounts accounted for 18% of OPUS revenues, up from approximately 10% in prior years. New accounts contributed 23% of revenues in the quarter, and order load was again strong. As discussed on our last call, we are investing in additional capacity and have decided to accelerate and expand this activity to ensure we are keeping ahead of demand.
We expect now to have four suites online by the end of 2019 and an additional nine suites by the end of next year, which will give us capacity to produce four to five times more columns per year than we had in place at the end of 2018. Our OEM proteins business also had an exceptional quarter, up over 40% organically. Demand for our Protein A ligands was especially strong, which was the main contributor to the over performance in proteins in the quarter. As discussed on previous calls, we expect growth factor and ligand demand to be very strong in the first half of 2019 and decrease in the second half.
This view has not changed. We expect that the H2 proteins business will be flat year on year as our two main accounts have secured a significant amount of their annual demand in the first half of 2019. 2019 will be the first year since 2015 where we will see growth in proteins with growth now expected to top 10% for the year. As we look to the second half of 2019, our focus will be on new product launches, capacity expansion and success of C Technologies integration.
We are very excited about our upcoming TFDF product launch, where we will focus the technology on mAb applications. Our ATF controller and next-gen SIUS products are also set to launch, which will provide good momentum as we kick off 2020. As our business has accelerated here in 2019, we have invested in people and in capacity. We've added approximately 100 people to the organization year to date, excluding C Technologies, and we are on track to complete three major capex programs in 2019.
The first one is the SAP implementation here on the East Coast in Waltham and Marlborough which will happen in quarter three. The relocation of our ATF manufacturing from Waltham to Marlborough by the end of the year and the addition of the four OPUS suites to support our rapidly expanding chromatography business. These additions and investments will lower our operating margins in the second half of 2019, but we still expect to see strong margin expansion of approximately 200 basis points for the calendar year. In summary, we had an excellent start to the year.
We have delivered on our financial goals, executed on a key M&A, invested in people and infrastructure to scale our company to the next level, and finally, positioned ourselves for the future through a series of equity and debt financings as we continue to execute on our blueprint for growth, which is centered on technology leadership and bioprocessing through internal development and M&A. I'll now turn the call over to Jon for a financial update.
Jon Snodgres -- Chief Financial Officer
Thank you, Tony, and good morning, everyone. Today, we are reporting our financial results for the second quarter of 2019, as well as updating our financial guidance for the year. Unless otherwise mentioned, all financial measures discussed today reflect non-GAAP measures. Before diving into our quarterly results, I'll take a few minutes to provide some additional color on C Technologies and our recent financing activities, including the impacts on cash, share count and EPS.
First, on May 31, we closed on our acquisition of C Technologies using $195 million of cash and issuing approximately 800,000 new shares of Repligen common stock. We now expect C Technologies impact on GAAP fully diluted EPS to be a loss of $0.15 to $0.16 versus our prior estimate of a loss of $0.04 to $0.06. This change is associated with the purchase accounting treatment and timing of certain deal-related costs that are cash-neutral to the overall deal. On an adjusted basis, we now expect C Technologies to be $0.06 to $0.07 accretive to our 2019 earnings per share, compared to the previous range of $0.05 to $0.07.
The reconciliation of GAAP to non-GAAP EPS for C Technologies alone includes the following approximate adjustments: inventory step-up charges of $0.03 per share; acquisition and integration costs of $0.20 per share; and intangible amortization of $0.06 per share, partially offset by a $0.07 tax effect of these adjustments. Next, in the second quarter and here in the start of the third quarter, we completed two follow-on offerings to provide the company with financial flexibility. In May, we executed on an equity raise. And in July, we executed on a concurrent equity and convertible debt offering.
In conjunction with the convert, we completed a private exchange for 80% of the outstanding notes from our May 2016 convert. We also issued a redemption notice for the remaining 20% of the outstanding notes, which we expect to close in September. The result of the combined effect of our offerings and redemptions is a net $484 million in cash and the issuance of an estimated 7.3 million new shares. The overall impact to Repligen of these financing activities since our first quarter report is as follows.
First, we added approximately $290 million of cash to our balance sheet to use for future business needs and opportunities, net of the cash used to acquire C Technologies and settle our 2016 notes. Second, we improved our coupon rate with our new convert, which is at 0.375%, compared to 2.125% on our May 2016 notes, which will lower our quarterly cash interest expense. And third, on our GAAP P&L, we expect to record an estimated $5.7 million in debt extinguishment expense in Q3, and we are estimating noncash interest expenses of $5.1 million in the second half of 2019, both of which will be excluded from our adjusted non-GAAP P&L. Moving now to our second quarter and first-half 2019 financial results.
As you've seen in our press release this morning, we delivered very strong financial performance for the second quarter and are again raising both our top and bottom-line financial guidance for the year while we continue to ramp up our investments in capacity, systems and personnel to stay ahead of strong market demand. Specifically, we delivered another record quarter with revenues of $70.7 million with organic growth of 46%, net of a 2.6% headwind from foreign exchange. We also increased adjusted operating income by 159% year over year to $20.1 million and realized a 1,200-basis-point year-over-year improvement in adjusted operating margin, up to 28.4%. Finally, on the bottom line, we reported 122% year-over-year increase in adjusted EPS to $0.31 per fully diluted share.
As Tony mentioned earlier, our three product franchises, filtration, chromatography and proteins, continued to perform very well with each of the product franchises growing at least 40% organically compared to the second quarter of 2018. On a regional basis, for the year-to-date period, direct product revenue growth was strongest in both North America and Asia at approximately 60%, and Europe grew at 20% versus a very tough 2018 comp. Overall, 57% of our direct product revenue for the year-to-date period came from North America with Europe and Asia accounting for 26% and 17%, respectively. Based on market strength and overall visibility in the third quarter, we continue to expect strong performances from our filtration and chromatography businesses in the second half of 2019.
And as Tony mentioned, we expect a slowdown in proteins in H2 given the exceptional growth in the first half of the year. Overall, for the year, we expect that filtration and chromatography will grow at greater than 35% organically, and proteins will grow at greater than 10% organic. Now moving down our income statement. Adjusted gross profit for the second quarter of 2019 was $41.4 million, representing an increase of 54% or $14.6 million compared to the second quarter of 2018.
Adjusted gross margin of 58.6% was a result of strong operational execution, favorable product mix and timing of volume increases that were ahead of our plant capacity investments and systems investments, which will impact us in the second half of 2019. For the first half of 2019, adjusted gross margin for the company was 57.4%. We expect second-half 2019 gross margins to be approximately 200 basis points lower than the first half due to planned increases in expenses related to facility expansion in our Waltham facility, depreciation expenses from investments in plant capacity and our new SAP system and increases in headcount to support higher product volumes flowing through our factories. With respect to operating expenses, adjusted research and development costs for the second quarter of 2019 were $5.1million, compared to $5.7 million in the 2018 period.
The reduction compared to the second quarter of 2018 was due to timing of a large 2018 investment and new ligand technology with Navigo GmbH. Overall, adjusted R&D expenses for the second quarter were 7.3% of revenue, and adjusted R&D spend is expected to increase through the second half of the year to support key investments and developments of our new ATF controller technology, TFDF systems, as well as investments in C Technologies pipeline. We expect an overall adjusted R&D expense of approximately 7% of revenue for the full-year 2019. Moving to SG&A.
Our second quarter of 2019 adjusted SG&A expense was $16.2 million, compared to $13.4 million for the second quarter of 2018. The 21% year-over-year increase in adjusted SG&A was tied to the expansion of our commercial organization and infrastructure teams, as well as the addition of C Technologies to Repligen. We also expect plant increases and expenses in the second half of 2019 in adjusted SG&A, supporting the expansion of facilities in Waltham, depreciation related to our SAP implementation and other IT investments, as well as for the addition of C Technologies to our business. Overall, we expect full-year adjusted SG&A expenses to be approximately 26% of overall revenue, and this is reflected in our full-year 2019 guidance.
For the full year, we expect total operating expenses to come in at 33% to 34% of sales with adjusted operating margin expansion in the range of 200 to 300 basis points. Moving now to adjusted income and EPS. As I mentioned earlier, our second-quarter 2019 adjusted operating income was $20.1 million, a 159-point increase -- percent increase, compared to $7.8 million reported in the second quarter of 2018. Our adjusted operating margin was 28.4%, a 1,200-basis-point improvement over the second quarter of 2018.
Beyond sales volume flow-through and favorable product mix, second-quarter operating margin strength benefited from the pacing of investments and new hires and operations, as well as in IT systems, which are more heavily weighted toward the second half of the year. Adjusted net income for the second quarter of 2019 was $15.3 million, an increase of 147%, compared to $6.2 million in the same period in 2018. Adjusted EPS increased $0.31 per fully diluted share for the second quarter of 2019, up from $0.14 for the second quarter of 2018. Our cash and cash equivalents, which are GAAP metrics, were $208.9 million at June 30, 2019, reflecting first half of 2019 net cash generation of $15.1 million, inclusive of our May equity offering proceeds of $189.6 million, less $195 million of cash -- restricted cash and deal costs paid for the acquisition of C Technologies.
In the first half of 2019, we generated free cash flow of $18.4 million, inclusive of $27.5 million of operating cash flow, plus $9.1 million of capital investments, primarily related to our ongoing capacity expansion initiatives and SAP implementation program. In addition, our full-year 2019 cash balance guidance will reflect an increase of approximately $290 million from the net cash proceeds from financing activities. Now moving to our 2019 full-year guidance. Our GAAP to non-GAAP reconciliations for our 2019 financial guidance are included in the reconciliation tables in today's earnings press release.
As previously mentioned, unless otherwise noted, all 2019 financial guidance discussed will be non-GAAP. Please also keep in mind that our 2019 guidance may be impacted by fluctuations in foreign exchange rates beyond our current projection of 1% headwind on sales. Today, to reflect our acquisition of C Technologies and in recognition of strong market conditions and overall execution, we are increasing our 2019 full-year revenue guidance, a GAAP metric, to $264 million to $268 million, an increase of $28 million from the midpoint of our previous range and reflecting growth in the range of 36% to 38% as reported and 29% to 31% on an organic basis. We are holding our adjusted gross margin guidance for 2019 to 56% to 57%, and we are increasing our non-GAAP operating margin guidance to 22.5% to 23.5% of revenue.
We are increasing our guidance for adjusted operating income to $60 million to $62 million, an increase of $7.5 million at midpoint from our previous guidance. In terms of other income and expense, we now expect to see a net full year of income of approximately $2 million, reflecting the reduction in cash interest expense from our new convertible debt instrument, as well as interest income from additional cash on hand. We are increasing our 2019 adjusted income tax expense to be approximately 24% of adjusted pre-tax income. This increase in our annual tax rate is related to effects from the extinguishment of our May 2016 convertible debt, as well as changes in the company's methodology for calculating its non-GAAP financial measures to reflect certain tax effects related to acquisition and integration costs, inventory step-up charges, intangible amortization and noncash interest expense.
We are also increasing our full-year 2019 adjusted net income by $5.5 million at midpoint to a new range of $47 million to $49 million and the midpoint of our adjusted EPS by $0.09 to a range of $0.94 to $0.98 per fully diluted share. Our adjusted EBITDA range is also being increased by $7.5 million at midpoint to $68 million to $70 million for the full-year 2019 with depreciation expenses expected to be approximately $7.5 million and intangible amortization expenses estimated to be approximately $13.5 million, inclusive of C Technologies. In terms of weighted average fully diluted share count assumptions for 2019, we have increased to 50.1 million weighted average fully diluted shares at year end, which incorporates the estimated impact of our Q2 and Q3 financing activities, as well as our purchase of C Technologies. Weighted average fully diluted shares are expected to be approximately $52 million in Q3 and $53 million in Q4.
The company is maintaining its 2019 full-year capex investment guidance at $18 million to $20 million. We are increasing our 2019 year-end cash and cash equivalents, a GAAP metric, to be in the range of $510 million to $520 million, which includes cash generation from our base business, net proceeds from our recent equity offerings and convert activities, less the cash component of the purchase price of C Technologies and related acquisition fees. This completes our financial report and guidance update, and I will now turn the call back over to the operator to open the lines for questions.
We will now begin the question-answer session. [Operator instructions] And the first question comes from the line of Tycho Peterson of JP Morgan. Please go ahead.
Hey, good morning. Tony, I'm wondering if you could talk a little bit more about the protein business, up 40% this quarter? I think you started out talking about it being flat to down on the year. You're now talking about it being greater than 10% for the year. So can you talk about what you saw in the quarter on protein? And then, I guess, going forward, should we think about it being back to kind of growth mode, looking a little bit beyond the back half of the year?
Yes, sure. So if you think about the proteins business, Q1 and Q2 were actually very different. In Q1, we saw a very strong growth factor business with reasonable single-digit growth in the ligands piece. And then when we got to Q2, it really was all about ligand demand right across the board with both GE and Milllipore having very strong demand in the quarter.
We were expecting that the first half of the year was going to be stronger based on forecast. It definitely came in a lot stronger than we were forecasting. And when we look at the second half of the year and we look at the forecast, we can see year-on-year H2 2019 versus H2 2018, that's essentially going to be flat. And obviously, with the strength we saw in the first half, overall growth for the year is definitely going to top 10%.
Now that said, when we move into 2020, as we've spoken about in the past, GE has the option to move up to 50% of their proteins demand, ligand demand in-house. So we expect, as we go through 2020, that some of that volume is definitely going to move across. So I think we'll have a better idea, Tycho, when we get to the end of the year and early February next year exactly what the GE demand is going to look like in 2020. So for now, I think it's a very good year in 2019.
I don't think it reflects where proteins is going to be in the future. And I think our real future in proteins is really around the strategy we put in place last year with Navigo and Purolite and developing our own portfolio of affinity ligands, and we expect that those will begin to ramp up. We're seeing some ramp this year, but we'll definitely see an additional ramp next year.
And then it was interesting to see gene therapy. I think you called it out at 25%. And last time, I think it was 15%. So can you just talk a little bit about what you're seeing in that market, how quickly you think you can kind of capture share? And what kind of investments you need to make around the gene therapy business?
Yes. The gene therapy market, a year ago, when we talked about it, it was really beginning to take off, but it was still a very small percent of our overall business. The 25% comment in my prepared remarks was around the Spectrum business in Q2. But for sure, when you look at all our products, we're in a good position in gene therapy.
And just to be clear, our focus in gene therapy is really around viral vectors and plasmid manufacturing, less so in the CAR-T side of the equation. But in general, I think we have three or four products in our portfolio that really address some of the pain points that exist in gene therapy today. So our OPUS pre-packed columns, people really like the convenience of being able to have all the resins pre-packed and ready to go. Our ATF and hollow fiber product lines are doing very well, both upstream and downstream.
Our flat sheet cassette business, which is the TangenX business, is well suited to downstream filtration. And when we look at our systems business that we really pulled together in the second half of last year, we're able to sell now systems with our consumables into this customer base. So when you look at overall gene therapy for Repligen, I would expect that probably by the end of the year, close to 15% of Repligen revenue will be coming from gene therapy accounts.
OK. And then lastly, are you able to give an order growth rate? I know you gave us one last quarter. I didn't hear that in the prepared comments.
Yes. Across the board, I mean -- or I don't have an exact growth rate, but orders were very strong across the board. Very similar to what we saw probably coming out of Q4 into Q1, probably not as strong as the Q2, but still a very healthy pipeline of orders going into Q3 and Q4. So we're -- I think there's a lot of confidence about our numbers that we've put out for the second half of the year, and a lot of that is coming from a strong order load coming out of the first half into second half.
Your next question is from the line of John Kreger of William Blair. Please go ahead.
John Kreger -- William Blair and Company -- Analyst
Hi. Thanks very much. Tony, just building on your comments about the proteins business in 2020. So given the substantial ramp in growth that you've seen this year over the last, can you just talk about some of the key bottlenecks you've got in the organization to growth? I'm assuming there are some.
And are there any other kind of key things you want to call out as we think about '20?
Yes. So the -- I think the question is probably broader than proteins, John. So if I look at investments we need to make, we're actually making them. So as we finished off 2018, it was clear to us as we saw the order load.
There was a few areas that we wanted to invest. And one was definitely on the pre-packed column side. So we've been ramping up with people in the first half of the year. So we've been able to add in a second shift for OPUS, and that's really increased our overall volume of output.
But I think as we see visibility from customers around what they want, in 2020, 2021 and 2022, it became clear to us that we really needed to scale OPUS manufacturing by four- to fivefold. And that's why we're adding in four suites by the end of this year, an additional nine next year. So that's a big investment for us but fully supported by the demand that we're seeing out in the marketplace. To really free up some of that demand, we made the decision sort of mid-Q1, early Q2 that we would utilize our Marlborough facility, which is really our center of excellence for filtration and move the ATF products and centralize all filtration products outside what's going on in Rancho and hollow fibers in Marlborough.
That will be in place by the end of the year. And then the rest of our investments have really been around systems, right? So SAP is a big investment for us. We're really happy with the progress we've made. We're at a point now where the East Coast will go live in Q3, and then we'll basically transition then over to bringing the legacy Spectrum sites online in first quarter of next year.
So they are the main investments that we're looking at. I think they're going to play out probably not only this year, but also into 2020. But it's what is needed to happen, in addition to bringing on additional people so we can stay ahead of the demand curve.
Great. So if you think about your direct business, do you have a view on the sort of sustainable growth that it could support? I'm assuming it's too soon to have a view on sort of demand trends into next year. But what -- could the direct business support, let's say, 20% growth? Or is it too soon to call that?
Yes. So it's definitely a little early. But I think given what we've done, and if you look at 2017, our filtration and chromatography businesses had organic growth of 20% plus. Last year, it was north of 20%.
This year, you can see, obviously, through the first half of the year, it's about 35%. So I think a 20% growth for chromatography -- organic growth for chromatography and filtration is absolutely a reasonable assumption. That's something that we aim to do. Obviously, we'll have some headwinds next year with the proteins business.
And obviously, to be able to counter that, we have to continue to overdrive on filtration and chromatography. And obviously, the C Tech piece begins to play a role next year as we get a full year of C Technologies in the business.
Great. And one last one. When do you expect to roll out the new TFDF product?
Yes. That's going to happen toward the end of this quarter. So we're in the final stages of the marketing rollout. So by the time we get to November, we'll be able to give everybody an update on the first couple of months of TFDF.
Your next question is from the line of Matt Hewitt of Craig-Hallum Capital Group.
Matt Hewitt -- Craig-Hallum Capital Group LLC -- Analyst
Good morning. Congratulations on the strong quarter. Just a couple for me, and the first one being a point of clarification. I think last quarter, you talked about adding six large-scale manufacturing suites for OPUS in Massachusetts.
It sounds like you're going to expand that further. Did you say four online by the end of this year and nine by the end of '20, so a total of 13. Or is it a total of nine, so four this year and five next year?
So you're right. It's 13. It's four this year and nine next year. We will add essentially 10 additional suites into Waltham and three into Europe.
And one of the decisions we made based on the continued uptick in demand was to centralize our OPUS manufacturing, not in Ravensbrück, but in Breda, where we actually own the facility, and we have a lot more space. So that was a small shift that we made but I think an important one for us for the long-term growth for OPUS and to be able to serve the European customer base.
OK. Thanks for the clarification. And then as part of that expansion, are you factoring in maybe opportunities to expand that OPUS line? Or is this just for the -- is the expansion just for the existing OPUS line?
Well, it covers both. It's definitely the existing product lines. But obviously, we have products in development that will continue to expand the overall OPUS portfolio. So it will manage both.
OK. All right. And then maybe last one here. As of last quarter -- and you may have just touched on this in the prior response.
But at the time of your last call, it sounds like you were evaluating whether to transfer some additional products to the Marlborough facility. Are you still looking at that? Have you made any decisions, anything on that front?
Yes. I think when we spoke the last time, we've always said that the Marlborough facility is our center of excellence for filtration. And the Rancho facility, which is the Spectrum facility, that's our center of excellence for hollow fiber modules. So it made sense to us, as we looked at the capacity expansion plans that we have in place, to move the ATF filtration basically 20 miles down the road to Marlborough and centralize it where we've all the engineering people together.
We have the operators together, and we can really leverage the team that we have there.
Got it. All right. That's it for me. Thank you.
Thanks, Matt.
Your next question is from Brandon Couillard of Jefferies. Please go ahead.
Thanks. Good morning.
Morning, Brandon.
Tony, if we just look at the outperformance in the second quarter, clearly, based on other peer reports, the markets in bioprocessing are clearly doing quite well. How much would you attribute to just a better market environment versus Repligen-specific drivers?
I definitely think it's a bit of both. When you look at the overall market environment, it's really accelerated from where our industry was in the first half of 2017. And you could almost say all of 2017 and through the first half of 2018 was pretty tough for everyone. But then we saw last year, as we got into the second half, that our organic growth began to pick up, and I think that's a reflection, too, of the strength in the market.
So for me, we look at it really from a mAb point of view. We think the gene therapy customer base has accelerated, right? There are a lot of companies really working on viral vectors. So that's absolutely helped. We also have a portfolio of products that are very differentiated in the marketplace.
So I think that's the piece that gives us the kind of the above-market growth that we've seen over the last few years. So when you look at what we're doing with OPUS, what we're doing with ATF, what we're doing with our hollow fiber portfolio and systems, it's pretty unique. And I think that's what allows us to be able to grow at above-market growth rate. And then I think the final part was the commercial integration that we did last year.
We paced it. We didn't try and integrate Spectrum and Repligen sales teams all at once. Remember, we went sort of Q1, Asia; Q2, Europe; Q3, North America. So when you think about the last sort of 12 months, we've really just gone through 12 months now with fully integrated commercial team.
And that has really helped us having everybody selling the whole portfolios complemented and supplemented by specialists.
And then given your balance sheet capacity, you sort of speak to your willingness or appetite to perhaps pursue another M&A opportunity kind of what the funnel looks like there and just internally, your ability to perhaps absorb another deal?
Yes. So M&A, obviously, it's a big part of what's gotten Repligen to where we are today. Purely with $500 million in the bank, we are in a good position as we look at assets. The M&A situation in 2019 is no different than it was in 2018.
We have an active list of companies that we're talking to, but it's no different than 2018. We'll continue to talk if there's a really good opportunity that pops up. I think we're well-positioned to be able to execute on it. And obviously, a lot of focus right now is on the C Tech integration, but I think it is probably more straightforward than the Spectrum integration, which was a much bigger integration for us.
So we'll see what happens. But I think expect over the next few years that we'll pace acquisitions very similar to what we've done in the past.
Your next question comes from the line of Paul Knight of Janney, Montgomery, and Scott. Please go ahead.
Paul Knight -- Janney, Montgomery, Scott -- Analyst
Hey. Tony, on the CT transaction, I guess can you talk about basically how easy you think this will be to integrate in your customer list? And is it -- they have seven salespeople. You need to sign up all seven and three are done? And could you talk basically about how easily you can tuck it into more and more installations in the industry as you have done with your other acquisitions?
Yes. So C Tech is we're really early innings of doing the integration. So Craig, the C Tech owner and who stayed on and is running the whole business, they've built up a great -- not only a great portfolio of products, but a really great customer base. One of the challenges they have is that the actual selling organization, number of salespeople is relatively small.
So one of the things that we have to do to really help them grow beyond what they've been able to do over the last, say, four or five years has really built up this commercial team. And that's what our No. 1 focus is. And our goal is to bring on around seven salespeople.
So think of them as specialists, very like our BSS model that we have for filtration and chromatography. They'll come online by the end of the year, and that will position us well for 2020 to be able to grow the business with dedicated specialists in North America and dedicated specialists in Asia and dedicated specialists in Europe. And so the call points, there are some overlap on the call points, especially in the manufacturing setting, but they also have some new call points in the quality-control labs, in the formulation labs where we don't call on today. So I expect that when we get into 2020 that our existing bioprocess sales team will be working hand in hand with the specialists.
Let's call them C Tech specialists, which really are process analytics specialists to call on the -- hit the call points where -- that are in common, but also be able to accelerate with some of the new call points, which will be in quality control and formulation. So it's a bit of a process, Paul. It's going to take us the best part of this year to really set ourselves up for 2020.
Your next question comes from the line of Steve Schwartz of First Analysis. Please go ahead.
Steve Schwartz -- First Analysis -- Analyst
Good morning, everyone. So the two questions I have actually expand on some previous questions, if we could. Just with respect to, Tony, your comments to Tycho's question about gene therapy. In the cell and gene therapy arena, do those orders to the products you ship, are they significantly different from your traditional markets, if you will, of mAb production, protein production? Are the unit pieces that the components smaller and maybe in higher numbers for an order count, that sort of thing? That's the nature of my question.
Yes. So the products are essentially the same. I just think some of the gene therapy accounts are working on a smaller scale in, say, some of the mAb accounts, but it's very similar. And so when we're selling OPUS columns, we might be selling eight-centimeter diameter to 30-centimeter diameter columns.
And some of the mAb processes, we might be selling 45, 60s and 80s. So yes, there's a little difference in terms of the size, but it's essentially the same products going into upstream and downstream applications. And I think that's one of the real benefits that we have is that we have a portfolio of products that are very applicable into the gene therapy space, and our sales guys are very aware of where some of those opportunities are. And I think, we've been able to execute on that.
And I think very similar to our peers in the space, I think everybody is very, very busy working with the gene therapy customer base.
OK. Fantastic. Yes. And 15%, is 15% of revenue.
So -- but glad to hear about that makeup. What makes that up? Second question, just building on Brandon's question with respect to M&A activity in your capacity there. When you talk about the integration and the transformation of C Tech to public company standards, is that being done by the people who carry other roles in the organization? So is it an add-on activity for your staff? Or are you hiring people specifically to handle that activity? And what is your capacity in that regard, that side of maybe executing on the $290 million net that you have?
Yes, Steve. So I'll start with that one. In terms of the capacity to handle the changeovers to public company standards, we're leveraging some of the resources that we have internally to help position the team and guide them to where we need to be to get up to Repligen standards. But we're also hiring people locally to help administer that and put those programs in place.
So it's really a combination of the two, guidance from the current team that we have and leveraging that. And then actually, the heavy lifting and implementation work is mostly going to come from that local team, and we're really happy that we've made one excellent hire so far, and we continue to look for others. And then I'll pass it back over to Tony on -- in terms of M&A.
Yes. Maybe, Steve, do you want to repeat the question on M&A? I'm not sure.
Yes. Just so -- so with that being said about who is executing these activities and what's your capacity then, now that you have -- you've taken out some additional cash, and you have some more powder in the CAG, if you will?
I think it's similar to what I said earlier, I don't think 2019 is any different than 2018. We're actively talking to targets, and we'll continue to do that. We were doing that last year as well. And it's just -- it's all around timing.
It's all around finding the right fit and then reaching a sort of an agreement on what works for both companies. So it's no different. I really think that our pacing on M&A is going to continue to be similar to what you've seen over the last four or five years. Every 12 to 18 months, I expect that we'll be executing on a deal.
Yes. If you could flavor your M&A pipeline for us at this point. Is there any particular bias that you sense with respect to filtration, chromatography or the now newly developing area for you of process analytics?
Yes. I'm sure you'll smile as you hear my answer. But in general, we see opportunities in filtration. We definitely see opportunities in chrom.
And obviously, we're just starting in the world of process analytics. And so when we talk to customers, it's our two companies, they span all three, right? And so we're not trying to target one versus the other. It's really trying to address some of the gaps that we see that -- and opportunities that we think are out there.
No. That's very helpful. OK. Thanks for taking the questions.
Your next question comes from the line of Raghuram Selvaraju of H.C. Wainwright. Please go ahead.
Good morning. This is Edward on for Ram. Just a clarifying on the last point about process analytics. Considering that C Technologies are still being fully integrated into the process.
I'm wondering if you're considering -- it sounds like you're still considering M&A into the process analytics space? And might that change as you fully integrate C Technologies and see where they fit in with the synergies around the entire business?
Yes. Like all our product lines and all of our businesses, we jumped into the process analytics space. C Tech made a ton of sense for us. We believe in process analytics.
We definitely would like to continue to expand that portfolio led by Craig, and it's just really one of those timing things, and we'll see what happens over the next couple of years.
OK. And just a point that you've previously mentioned about having a $2.1 billion total addressable market represented by the segments that you're currently in. I'm wondering if that's considering what you currently have on hand? Or whether there are -- whether you're looking to expand into other areas that would fully bring you up to that $2.1 billion total? Or if that $2.1 billion addressable market is based on things that you would be pursuing in the future?
No. It's definitely based on where we are today, and it's our addressable market today based on the products we have in our portfolio and where we're going with those products.
OK. So the future addressable market would just increase based on some of the things that you're seeing for any M&A activity or how the market might shift in the future?
Yes, correct.
OK. Do you have any guidance toward how big that market might be? Or is it entirely dependent on how things might change?
I think it's really entirely dependent on how things might change, but the bioprocessing market is way bigger than $2.1 billion, probably around $8 billion to $9 billion. So you can imagine there's a lot of runway to jump into some other areas in the world of bioprocessing that would expand our overall TAM.
And congrats on another great quarter.
And this concludes our question and session. I would now like to turn the conference back over to Tony Hunt for any closing remarks.
I'd just like to thank everybody for joining us today. Obviously, a very strong start to 2019. I think we're really well-positioned also for the second half of the year, and we look forward to getting back on the call with everybody in November and bringing up to speed on where we are as we finish off 2019. So thanks, everybody, for joining.
More RGEN analysis


Blue Raspberry by Salt Pop 30ml vape juice is a euphoric Blue Raspberry Fruit Salt Nicotine Flavored E-Liquid. Salt Pop Blue Raspberry 30ml Nic Salt eliquid is your answer to the flavor you have been looking for all along! Blue Raspberry Salt Pop Salt Nicotine e-juice will tantalize your taste buds in a way like you have never experienced before. Blue Raspberry Salt 30ml e liquid tastes like a handful of Blueberries and Raspberries mixed together in perfect harmony. Blue Raspberry 30ml Salt Pop e juice is smooth on the inhale and the exhale, making it a super enjoyable vaping experience for all vapers!


text:
Q: SQL-query to find articles with at least one of the listed tags I have 3 tables: articles, tags and article_tag (the one which connects them).
I'd like to find all articles that have some (or all) of the tags listed in the query and order them by the number of matched tags. Is it possible?
Example in english:
Query: Find me all articles that have at least one of these tags "jazz, bass guitar, soul, funk", order them by the number of matched tags.

Output:
Article 1 (jazz, bass-guitar, soul, funk)
Article 2 (jazz, bass-guitar, soul)
Article 3 (jazz, bass-guitar)
Article 4 (funk)

A: Probably something like this:
select articles.article_id, count(tags.tag_id) as num_tags, group_concat(distinct tag_name separator ',') as tags
from articles, article_tag, tags
where articles.tag_id = article_tag.tag_id
  and article_tag.tag_id = tags.tag_id
  and tags.tag_name in ( 'jazz', 'funk', 'soul', 'Britney Spears' )
group by articles.article_id
order by count(tags.tag_id) desc

A: select a.* from articles a,
 (select article_id, count(*) cnt from article_tag at, tag t
  where t.name in ('jazz', 'bass-guitar', 'soul', 'funk')
  and at.tag_id = t.tag_id
  group by article_id) art_tag
where a.article_id = art_tag.article_id
order by art_tag.cnt desc


One really useful caution he gives involves the downhill trip. He says, and I agree, that most hiking injuries happen on the way down. So how do you get tired kids to pay attention and slow down on the return trip?
I jokingly tell my kids that anybody who falls on the way down doesn't get ice cream, our traditional post-hike treat.
The downhill slog is a good time to stop for a bit of tree identification or to watch the chipmunks. But whatever you do, don't let kids run down trails unless you are looking forward to an emergency room visit.
On this topic, one more suggestion. With younger children I let them lead on the way up so I can be right behind if they slip, but I lead on the way down, where I may be able to help if they tumble and I can slow the pace.
Later Aprill wisely includes a section about hiking with teens. Just getting a teen to join you on a hike can be a success. Maybe you can use a hike with teens for some of the" big talks" that are hard to have at home.
And that is the most important reason to take your child hiking: spending time together.


Shed new light on the interaction between the professional operators and the healthcare system.
Develop, foster, and expand comprehensive research that increases our understanding of the healthcare environment and the role of clinicians in this setting. Research will contribute to improvements to the overall system.
Educate a new generation of practitioners.
The center aims to support and encourage young researchers from various disciplines to add their voice and perspective to the HSI process in healthcare. The center will also promote teaching and training in associated areas, particularly via masters, doctoral, and post-doctoral fellowships. These efforts will help to shape the field by inspiring and educating the next generation of practitioners, researchers, and educators, committed to implementing HIS as a means of improving healthcare systems.
The center will promote collaboration across varied disciplines. It will foster collaborative ventures between the center's researchers and collaborators from other research centers, leading scholars, and institutions in Israel and abroad; and promote the sharing of knowledge, advice, and experience for the benefit of all.
Contribute to public policy, public awareness, and education.
The center will serve as a catalyst for change by disseminating scientific knowledge and conducting research with policy applications and the potential to serve the public interest by promoting positive change in healthcare systems, through national and international conferences, workshops and seminars.
The center will provide services such as formative and summative testing to companies that develop medical devices. These services will help Israeli medical device companies develop and design products suitable for global markets. Such academic-industry partnerships will foster additional collaboration and help the center identify new services to offer.
There are significant challenges associated with complex healthcare systems, particularly the interaction between the professional operators and such systems, and the objectives mentioned above will help address these issues and contribute to a reduction of adverse events and improved care.


Metaxa 5 Star Brandy is a classic within the Metaxa range. Captured inside a beautiful bottle inspired by Greek architecture, Metaxa 5 star Brandy is full of life. Mellow and fruity with a soft taste and subtle woody aromas make Metaxa 5 star Brandy smooth and enjoyable.


text:
Q: How to manage building a huge source code that uses gnu autotools? I have multiple source codes which I have to cross-build and use together as one huge project. The building process of each source code is the same './configure-make-make install' commands with added parameters for cross compilation. So far I have been managing this by typing a really long configure command "./configure CC=....." in text editor and then copy pasting that on to terminal and running it. Then repeating the process for another source code. Taking care of multiple include paths, library paths, pkg-config paths etc. the process turns out to be very messy, error-prone and cumbersome. I have already used eclipse ide and have found no option for configuring the "./configure .." command to my need. Is there any elegant way to handle this problem? I would like a solution which will require me to write minimal amount of script/instruction.

A:
Is there any elegant way to handle this problem?

If you want to automatize the configuration and compilation of several sub-projects which are actually one project, I suggest you to use the GNU/Autotools canonical way to deal with it with is Nested Autotools project
In that way you can do a project which contains all the other projects in the following fashion:
./UmbrellaProject
   subproject1/
   subproject2/
   ...
   Makefile.am

Inside the parent project Makefile.am you will have a line at the beginning such as:
 SUBDIRS = subproject1 subproject2

More information at the GNU Automake docs


Change. Innovation. Shift. Something made different. An alteration.
Every July brings change to NSPE. We swear in our new officers, directors, and delegates. We review and approve a new budget. We set out new goals and charges for the Society and our committees, interest groups, and task forces. But, no matter what change we see in these activities, there are core principles that hold true year after year.
Stand against unethical practices and inadequate compensation.
NSPE has spent nearly half a decade taking a deep and critical look at our operations and governance through our Race for Relevance efforts. We have made some remarkable progress in these efforts and have a stronger and more vibrant organization because of them. We have looked introspectively at our house and put it in order. We have cleaned the cobwebs, purged much of the clutter, and now we are operating on an assumption and work load closer to maintenance rather than the complete overhaul we have focused on since 2012.
It is time for NSPE, our leaders, and our members to look outward and beyond ourselves. It is time to look at professional engineering as a whole and what we can do to leave our mark, to make a difference. As a profession, we need to ensure the public understands our necessary but often unnoticed role in protecting the public health, safety, and welfare; and we need to continuously build the trust that gives us our special status as licensed professionals.
It is also time for the profession to look more closely at our role in developing technology. As technology changes, the expectations of the public change and we, as professional engineers, must make sure we remain able to respond to these changes. We cannot become an obsolete profession, and we also cannot respond to these changes by just saying, "But it's always been done this way." That attitude is sure to be the fastest path to irrelevance.
We are engineers. We are taught the importance of being innovative. We must embrace change and find the best way to maintain our highest standards as professional engineers while also providing our services to our employers, clients, and society in the best, most efficient, and highest-value ways available. But this may also mean changes to the profession to attract and retain the best talent.
Might there be an entirely new way of organizing professional work—ways that are more affordable, more accessible, and perhaps more conducive to an increase in quality than the traditional approach?
If we concede that humans are indispensable in professional work, does it follow that all the work our professionals currently do can be undertaken only by licensed experts?
To what extent do we trust professionals to admit that their services could be delivered differently, or that some of their work could be responsibly passed along to nonprofessionals?
Is the traditional arrangement granting special status to the professions actually working? Are our professions fit for purpose and are they serving our societies well?
These questions are provocative and they are meant to be provocative. It is important that we, as professional engineers, are able to answer all of these questions.
Watch future editions of PE magazine this year for more information on NSPE's efforts to evaluate the future of our profession and updates on the work of the Task Force on the Future of the Profession.
NSPE provide access to the audible version of Susskind's book?
I suggest NSPE evaluate if it could obtain a license to "loan" the spoken version of Susskind's book on the future of professions to members. I now do much of my "reading" when driving, exercising, doing routine chores/tasks, etc - if one buys credits at audible.com, it costs about $11 to obtain the spoken version of the book.


Twist of Lime in conjunction with Evolve Research | Consulting has implemented a post interaction survey for an education services provider. The survey is initiated when the consultant closes an opportunity in their SAP system. A case is generated and sent to our server, where an email link is generated in Survey Shaper. The link is then emailed from our mailer to the customer, who completes the survey. Data appears instantaneously in a custom designed dashboard.


Regulator Ofcom has asked the top UK ISPs to explain why consumers often don't get the connection speeds they've paid for. In an effort to allay public concern over connection speeds, Colette Bowe, chairman of the Ofcom Consumer Panel, has written to the chiefs of the top six companies asking for their views and to come up with solutions that give customers clear information.
Ultimately Ofcom wants consumers to be able to find out what their connection speed will actually be as well as allowing customers to exit their deal if the speed is not in line with what they've been led to expect.
The decision to write to ISP chief executives follows increasing consumer concern about broadband speeds, says Ofcom. The regulator is concerned that the "up to" speeds advertised in broadband packages are often rather different from the actual, much lower speeds experienced by many subscribers.
In her letter, Bowe writes: "...we believe that broadband customers are not at the moment getting enough information. We are of course aware of the technical reasons for the "up to" terminology that you use. I would however like to have your views about how these technical issues might be better addressed in terms of giving clearer information to potential customers."
Ofcom says consumers need to be able to clearly understand what they are buying, what influences the performance of the product or services they are buying and how to do something about it if it doesn't live up to their expectations.


text:
Edtech Startup uLesson Education Introduces Junior Secondary School Library
Phantom 9 Full Unboxing Review: TECNO's Most Stunning Smartphone So Far
Bolt Nigeria again
Crypto Report: 35% of Nigerians have invested in crypto
*Crypto investors account for 35% of the Nigerian population aged 18-60 | *52% of crypto investors are under the age of 30
According to a crypto report released April 12, by KuCoin, titled, "Into the Cryptoverse Report: Nigeria Edition 2022, Nigeria stands head high in crypto adoption. Increasingly, more people are jumping on the bandwagon, becoming crypto investors themselves.
Crypto investors account for 35% of the Nigerian population aged 18-60. "According to our survey conducted in early 2022, 33.4 million Nigerians, which accounts for 35% of the population aged 18 to 60, currently own or have traded cryptocurrencies over the past six months. 70% of these crypto investors claim that they will likely increase their cryptocurrency assets soon. Another 6% of the country's population are interested in investing in cryptocurrency in the coming six months, suggesting that the cryptocurrency adoption rate might continue to increase."
37% of crypto investors have been trading cryptocurrencies for more than 3 years. "According to our survey, 37% of crypto investors in the country began trading cryptocurrencies more than three years ago. At the same time, 6% started trading cryptocurrencies more than six years ago. 26% of crypto investors have begun trading cryptocurrencies in the last 6 months."
52% of crypto investors are under the age of 30, embracing financial inclusion. "The youth unemployment rate in Nigeria increased to 53.4% in late 2020, driving youth to cryptocurrencies as their alternative financial solutions. Youth aged 18 to 30 accounts for 52% of crypto investors in the country. Technology and sports are the top hobbies of these crypto investors. YouTube, Telegram, and Facebook are the top social media used for cryptocurrency-related information. The high adoption rate of cryptocurrency also brings about gender parity in crypto investment; as our survey reveals, women account for 50% of crypto investors, on par with men."
The majority invest in crypto for the long run, 40% with an entrepreneurial goal. "Nigerian investors generally hold a long-term, practical mindset when it comes to cryptocurrency adoption. 62% of crypto investors perceive cryptocurrencies as the future of finance. 53% consider cryptocurrency to be a reliable, decentralised solution to store the value of their assets and mainly to use it for payments and transactions. 50% invest in cryptocurrency to gain higher returns in the long run. When asked about how they plan to use the profits from trading cryptocurrencies, 40% of crypto investors mentioned the attempt to start their businesses and improve the living conditions of their families. 36% invest in cryptocurrencies to add a source of income to their salaries. 34% strive to achieve financial independence, and 26% hope to rely on cryptocurrency as their main source of income without working additionally."
Nigerian crypto investors allocate the majority of their assets to cryptocurrency. "Our survey suggests that Nigerian crypto investors allocate an average of 60% of their assets to cryptocurrency, followed by cash/bank deposits (20%), foreign currency (7%), and other instruments. 52% of Nigerian crypto investors allocate over half of their assets to cryptocurrencies"
65% of crypto investors deposit fiat money into cryptocurrencies through peer-to-peer trading. "73% of crypto investors have bought cryptocurrencies with fiat over the past month. After the Central Bank of Nigeria issued an order barring banks from enabling crypto transactions in February 2021, the number of Nigerian investors buying cryptocurrencies with naira via peer-to-peer trading has been increasing. As of February 2022, 65% of Nigeria's crypto investors exchange fiat for cryptocurrencies via peer-to-peer transactions."
Finally, users look for ease of use, low fee and credibility in crypto exchanges. "When choosing which crypto exchanges to use, 45% of Nigerian crypto investors mention the ease of exchanging fiat for cryptocurrencies and the lower transaction fees to be their top considerations. A friendly user interface enabling investors to complete transactions quickly without effort is another appealing factor mentioned by 39% of crypto investors. The credibility of the crypto exchange endorsed by third parties and the perception of security is critical hygiene factors to facilitate user trust with the platforms, as mentioned by 37% of Nigerian crypto investors."
Correlation with the IMF report?
According to a research published by the International Monetary Fund (IMF) on March 25 titled, "Crypto, Corruption, and Capital Controls: Cross-Country Correlations", people in nations with greater levels of corruption are more likely to use cryptocurrencies than in other countries.
"We find that crypto-asset usage is significantly and positively associated with higher perception of corruption and more intensive capital controls," The IMF report said.
Notably, in 2021 Nigeria ranked 154th among the 180 countries listed in Transparency International Corruption Index. Making Nigeria the second most corrupt country in West Africa after Guinea.
Source: The Nation Newspaper
Also, according to the IMF report, nations that have severe capital restrictions, making it difficult to move money outside the country usually have an increased number of crypto users.
In an attempt to connect the dots, the Central Bank of Nigeria last week fined six banks ₦1.3 billion for engaging in crypto transactions. The CBN considers digital assets harmful to the country's financial system.
Apart from Nigeria being a corrupt nation and having severe restrictions on cryptocurrencies, there are other reasons to explain the high rates of crypto adoption.
A pointer is the limited access to affordable financial services in the country. According to the Kucoin report:
"While its economy relies heavily on remittances, a large proportion of its population does not have access to bank accounts, and money transfer is slow and costly."
Source: Cointribune
The standard of living in Nigeria has also been in a decline, with the rates of unemployment rising, caused by a combination of naira depreciation and the inflation of goods and services. Cryptocurrencies have become alternative solutions for the storage and transfer of assets.
Nigeria's relatively young innovative population also plays a big part in crypto adoption.


A professor based at a University in the United States has claimed that smartphones are revolutionizing the diagnosis and treatment of illnesses due to features and applications that make their ubiquitous small screens into medical devices.
Engineering professor at the University of Washington, Shwetak Patel believes smartphones can become a tool for medical diagnosis. He said, "If you look at the camera, the flash, the microphone - they all are getting better and better. In fact the capabilities on those phones are as great as some of the specialized devices."
Smartphones can already act as pedometers, count calories and measure heartbeats. But mobile devices and tablets can also become tools for diagnosing illness. Patel added, "You can use the microphone to diagnose asthma, COPD. (Chronic obstructive pulmonary disorder) With these enabling technologies you can manage chronic diseases outside of the clinic and with a non-invasive clinical tool."
The professor further claimed that the camera on a smartphone can be used to diagnose blood disorders, including iron and hemoglobin deficiency, he pointed to the success of an app called Hema-App - which was shown to perform comparably well as a non-smartphone device for measuring hemoglobin without a needle.
Researchers have expressed their desire for approval from the US Food and Drug Administration in order to implement it for wider use on a national scale. Professor Patel added that smartphones can also be used to detect bone disorders among the elderly. He said, "Your phone's motion picture sensor picks up the resonances that are generated. If there is a reduction in density of the bone, the frequency changes, which is the same as you will have in an osteoporosis bone."
The professor of engineering at the University of Washington believes an added benefit of these advancements is the fact they can empower individuals to manage their health on an independent basis. He added, "You can imagine the broader impact of this in developing countries where screening tools like this in the primary care offices are non-existent. So it really changes the way we diagnose, treat and manage chronic diseases."


The major sexual offences are to be found in the Criminal Law Consolidation Act 1935 (SA) and all references are to this Act unless otherwise stated. Special rules dealing with matters of evidence and procedure in sexual cases are to be found in the Evidence Act 1929 (SA) and the Criminal Procedure Act 1921 (SA).
For sexual offences specific to children, young people and vulnerable adults, see Offences against children, young people and vulnerable adults, Sexual offences. However, children, young people and vulnerable adults may also be the victims of the common and other sexual offences covered in this section.


An American reservist who had converted to Islam was in custody yesterday after it was found that he attempted to pass military secrets to al-Qa'eda in internet chatrooms.
Specialist Ryan Anderson, 26, a tank crew member of the 81st Armoured Brigade, was arrested on suspicion of "aiding the enemy" after the FBI, Justice Department and army began monitoring his communications in the hope of uncovering terrorist cells.
An army spokesman said Anderson had tried without success to "offer his services" by passing on information on the extent of American capabilities.
After he found no takers, Anderson, who studied Middle Eastern history at university, was arrested on Thursday. He is being held at a military jail in Fort Lewis, near Seattle, "pending criminal charges of aiding the enemy by wrongfully attempting to communicate and give intelligence to the al-Qa'eda network".
Anderson, whose unit is due to be sent to Iraq, does not appear to have been seeking payment for his services.
The investigation is focused on his conversion to Islam five years ago and reports from the local Muslim community that he had been advocating the use of violence.
His arrest is the latest embarrassment for the US military, which is already holding four of its personnel who served at Guantanamo Bay, Cuba, following similar investigations.
Aziz Junejo, host of an Islamic talk show on public access television in Seattle, said Anderson had originally joined a local Muslim e-mail group two years ago, using as his internet names Abdul Rashid and Gunfighter.
Mr Junejo said Anderson bragged about being an expert marksman and said he wanted to teach local Muslims to use assault rifles.


From 10 to 1,000! Everything Summer® is available to offer summer planning sessions to a variety of groups.
Planning sessions and talks can be tailored to specific age groups and topics, including summer camps, pre-college summer programs, teens and parenting. These group sessions can be held on-site or virtually.


text:
Get updates from Eve Tushnet delivered straight to your inbox
Gay Catholic Whatnot
Check out Eve's books!
I'll Come Speak!
Taking the Rough with the Smooch: Movie notes
February 23, 2017 by Eve Tushnet
Taking the Rough with the Smooch: Movie notes February 23, 2017 Eve Tushnet
A couple quick hits before we move to our main event, viz. a trip back in time to Gay 1986.
Habit: Do you like artsy bisexual '90s vampire movies, but found Nadja too cold, The Addiction too smart, and everybody too good-looking? Boy do I have a film for you. Habit follows a startlingly disheveled and run-down dropout type (writer/director/star Larry Fessenden) as he meets a cute early-'90s chick at a party and begins to wonder why people are disappearing. The direction is really sharp–the cuts and angles seem somehow especially emotional to me, driven by the characters' emotions rather than by artsy theories or something–and although the plot is very basic, the whole look and feel of the movie really does capture the gradually-then-suddenly disintegration of a life in addiction.
Game 6: I assume this turned up in my Netflix queue because it has Robert Downey Jr in it. If you are extremely invested in baseball and Don DeLillo (who wrote the screenplay) and you have nearly endless patience for self-absorbed men, you might enjoy this. There's one character who's interesting in theory: She at first seems to be the wise black woman who guides our hero to a better path, but in fact she turns out to be pushing a prosperity-gospel, "things will always go your way if you just have faith!" kind of message. I like that twist, I guess, but this wasn't a fun movie, sorry.
A couple nights ago I watched My Beautiful Laundrette (1986, London) and Parting Glances (1986, a bland version of New York) back to back. That's a strategy which is especially unflattering to Parting Glances, so I'll review them in the opposite order and try not to make comparisons (except for the one I totally just made in the parentheticals).
Parting Glances: One of the first movies to directly address AIDS, in the scrawny battered person of Steve Buscemi. He is the best thing about this film; he even has a real accent! Anyway, the action takes place in a tasteful, not sordid, version of '80s New York City, where everyone's shoulders slump for some reason, everyone has enough money, there's a certain dishonest grease of likability over the whole thing.
Gentle satire of the avant-garde art world which you've seen a thousand times already. Gay sexy stuff, which iirc was a big deal for this kind of well-meaning movie. A Pieta-like nude pose in the shower. Lots of dialogue that really takes you back: Remember how people used to say "lover"? Or saying, "They were–you know" instead of "gay"? Even in New York!
I don't know, the dialogue and acting and the whole idea of this thing were just not insightful enough. With the exception of La Buscemi, who radiates charisma, honestly. I also did like that the movie doesn't give closure. It commits to slice-of-life.
My Beautiful Laundrette: I'd seen this at least once before, in my troubled youth, and wondered if it would hold up. Holy cats it holds all the way up. Written by Hanif "Buddha of Suburbia" Kureishi, directed by Stephen "A Bunch of Things" Frears, this is the perfect mix of satire, sordidness, and heartfelt reconciliation. (I'm always saying that all I ask of a story is humor, sleaze, and repentance. This movie is like the jackpot of those things.) Also, "relevance" isn't really a virtue, but in many ways this feels like it was made in a kinder version of last month.
So, the story: Utterly charming Omar (Gorden Warnecke–why didn't he become a star? He sells this whole thing so well) is spending his days caring for his dissolute, depressed father (Roshan Seth) when one of his uncles offers him a job washing cars. "Mrs Thatcher will be happy" that you're working and off the dole, the uncle notes, and Omar gives this sweet smile that we'll see again and again in unexpected places throughout the film. He's a lopey guy, despite his slumping shoulders!, and there are lots of great scenes of men at work, I always appreciate manual-labor scenes. The car-wash job turns into an offer to run the uncle's decrepit laundromat, which Omar seizes as a chance to not only make '80s money, but pursue a slow, prickly, sexually-charged reconciliation with a childhood friend (Daniel Day-Lewis) who fell in with a gang of white supremacists.
Ahhh I loved this. Everyone's complicit–the sudsy laundromat scenes are symbolic not of cleanness but of labor. The Indian characters are all finding ways to manage their anger, redirecting it as despair or capitalist cynicism ("In this d–n country, which we hate, you can get anything you want… but you have to know how to squeeze the tits of the system") or determination ("I think I should harden myself," Omar says in an unintended double-entendre). There's just enough artsy cutting and angling, not too much; there's romance music when Johnny the skinhead first comes into the laundromat. Lol the '80s, so great about letting people want things. "I want everything now," Omar says, with a black eye from where his other uncle stepped on his face.
In our own differently-bad time this stood out: Omar really pursues Johnny, really makes himself vulnerable to rejection, without ever losing sight of the harm Johnny's done (he is offering real forgiveness, the kind that only comes when you acknowledge the wrong done), and all his open admiration for Johnny–the upward tilt of his head, his wide smile–makes him more self-confident, more free. There's a pretty strong message in the plot that repentance requires humiliation and suffering as well as amends. ("I want to forget all them things," Johnny says, and Omar's face gets really hard, angry and resigned and disappointed.) But I was even more struck by how the whole love story plays out from Omar's end, since I'm not sure I can think of other films that portray someone blossoming as he offers the second chance he's longed for years to give.
A tender movie in a tough world; an illustration of that Chris Arnade twitter thread about belonging; a movie in which homosexuality isn't respectable and doesn't seek to be (the parallels with the adulterous couple) yet/therefore a gay romance is a source of joy and healing. Class-conscious, really sleazy in its willingness to make class differences a source of sexual tension (there's a lot going on in that "When we were at school you and your mates kicked me all round the school and where are you now?" speech); a basically perfect movie.
England your England
gayer than a picnic basket
God bless the 1990s because no one else will
prepare for life in capitalist America: play Class Struggle--the Game
reading and repentance
Stephen Frears
work is a four-letter word
I review "I Am Michael," The James Franco Ex-Gay Biopic
February 28, 2017 "Corruptible Crown": I review "King Charles III"
Select a Category Art Best-Of Gay Catholic Whatnot Mackerel-Snapping self-obsessed Too much is never enough Uncategorized
Select a Month July 2019 June 2019 May 2019 April 2019 March 2019 February 2019 January 2019 December 2018 November 2018 October 2018 September 2018 August 2018 July 2018 June 2018 May 2018 April 2018 March 2018 February 2018 January 2018 December 2017 November 2017 October 2017 September 2017 August 2017 July 2017 June 2017 May 2017 April 2017 March 2017 February 2017 January 2017 December 2016 November 2016 October 2016 September 2016 August 2016 July 2016 June 2016 May 2016 April 2016 March 2016 February 2016 January 2016 December 2015 November 2015 October 2015 September 2015 August 2015 July 2015 June 2015 May 2015 April 2015 March 2015 February 2015 January 2015 December 2014 November 2014 October 2014 September 2014 August 2014 July 2014 June 2014 May 2014 April 2014 March 2014 February 2014 January 2014 December 2013 November 2013 October 2013 September 2013 August 2013 July 2013 June 2013 May 2013 April 2013 March 2013 February 2013 January 2013 December 2012 November 2012 October 2012 September 2012 August 2012 July 2012 June 2012 May 2012 April 2012 March 2012 February 2012 January 2012 December 2011 November 2011 October 2011 September 2011 August 2011 July 2011 June 2011 May 2011 April 2011 March 2011 February 2011 January 2011 December 2010 November 2010 October 2010 September 2010 August 2010 July 2010 June 2010 May 2010 April 2010 March 2010 February 2010 January 2010 December 2009 November 2009 October 2009 September 2009 August 2009 July 2009 June 2009 May 2009 April 2009 March 2009 February 2009 January 2009 December 2008 November 2008 October 2008 September 2008 August 2008 July 2008 June 2008 May 2008 April 2008 March 2008 February 2008 January 2008 December 2007 November 2007 October 2007 September 2007 August 2007 July 2007 June 2007 May 2007 April 2007 March 2007 February 2007 January 2007 December 2006 November 2006 October 2006 September 2006 August 2006 July 2006 June 2006 May 2006 April 2006 March 2006 February 2006 January 2006 December 2005 November 2005 October 2005 September 2005 August 2005 July 2005 June 2005 May 2005 April 2005 March 2005 February 2005 January 2005 December 2004 November 2004 October 2004 September 2004 August 2004 July 2004 June 2004 May 2004 April 2004 March 2004 February 2004 January 2004 December 2003 November 2003 October 2003 September 2003 August 2003 July 2003 June 2003 May 2003 April 2003 March 2003 February 2003 January 2003 December 2002 November 2002 October 2002 September 2002 August 2002 July 2002 June 2002 May 2002 April 2002 March 2002 February 2002 January 2002
Related posts from Eve Tushnet
From the Harlem Renaissance to the Overlook Hotel:...
Do We Really Need A New Translation of...
Eight "Catholic Horror Films" from a Global Church
The Unified Team: Three short movie reviews


Today I listed my first Wade figurine of the Mothers Goose nursery rhyme series. It's TheHouse That Jack built. Doesn't it bring nice childhood memories to you?
This is a part of wade figurines collection from the Canadian Red Rose Tea Premium series Nursery Rhymes (1971-79). Please visit our agardencottage shop for details and other figurines available.